Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.50 |
| ▸ | MEN1 | O00255 | 10/20 | 0.50 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | DDX3X | O00571 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17569636 | 1.00 | MAPT (0.54) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL19275515 | 1.00 | MAPT (0.54) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL7845384 | 0.86 | MAPT (0.43) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL19271236 | 0.84 | SMN1; SMN2 (0.59) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL17560485 | 0.83 | MAPT (0.40) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL17560484 | 0.83 | MAPT (0.40) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL17569528 | 0.83 | MAPT (0.40) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL3222110 | 0.83 | SMN1; SMN2 (0.64) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL31135773 | 0.83 | SMN1; SMN2 (0.64) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL19275673 | 0.83 | MAPT (0.49) | MAPTSMN1; SMN2NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723710-B2 | BORON GROUP-SUBSTITUTED ACYCLIC ALPHA AMINO ACIDS ARE USEFUL FOR INHIBITING A VARIETY OF ARINASE- AND NO SYNTHASE-RELATED DISORDERS, INCLUDING HEART DISEASE, GASTROINTESTINAL MOTILITY DISORDERS, AND PENILE ERECTILE DYSFUNCTION IN HUMANS. | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2004-04-20 | — | — | US | disclosed |
| US-20040063666-A1 | Compositions for inhibiting arginase activity | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2004-04-01 | — | — | US | disclosed |
| US-20030036529-A1 | Compositions and methods for inhibiting arginase activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2003-02-20 | — | — | US | disclosed |
| US-6387890-B1 | CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; SEXUAL DISORDERS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2002-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063666-A1 | Compositions for inhibiting arginase activity | ARG1, PDE3A, ARG2 | MAPT 4649/4885SMN1; SMN2 1295/4885NPC1 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.